8,100 Shares in Edwards Lifesciences Corporation $EW Bought by CTC Alternative Strategies Ltd.

CTC Alternative Strategies Ltd. acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 8,100 shares of the medical research company’s stock, valued at approximately $630,000. Edwards Lifesciences accounts for approximately 0.8% of CTC Alternative Strategies Ltd.’s holdings, making the stock its 26th largest position.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $266,000. Cetera Investment Advisers grew its holdings in shares of Edwards Lifesciences by 1.4% during the second quarter. Cetera Investment Advisers now owns 55,854 shares of the medical research company’s stock worth $4,368,000 after purchasing an additional 752 shares in the last quarter. Citizens Financial Group Inc. RI increased its position in shares of Edwards Lifesciences by 32.4% in the second quarter. Citizens Financial Group Inc. RI now owns 3,882 shares of the medical research company’s stock worth $304,000 after purchasing an additional 949 shares during the last quarter. Rockefeller Capital Management L.P. raised its stake in Edwards Lifesciences by 9.0% in the second quarter. Rockefeller Capital Management L.P. now owns 42,589 shares of the medical research company’s stock valued at $3,331,000 after purchasing an additional 3,526 shares in the last quarter. Finally, Citigroup Inc. raised its stake in Edwards Lifesciences by 30.3% in the second quarter. Citigroup Inc. now owns 1,385,415 shares of the medical research company’s stock valued at $108,353,000 after purchasing an additional 321,986 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $82.68 on Thursday. The company’s fifty day simple moving average is $82.32 and its two-hundred day simple moving average is $81.63. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The firm has a market cap of $48.02 billion, a PE ratio of 45.18, a price-to-earnings-growth ratio of 2.20 and a beta of 0.93. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The firm had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total value of $87,002.22. Following the sale, the vice president directly owned 33,934 shares in the company, valued at approximately $2,897,284.92. This trade represents a 2.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $84.92, for a total value of $1,103,960.00. Following the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at $3,371,239.08. This trade represents a 24.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 61,718 shares of company stock worth $5,236,281. 1.29% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have commented on EW. UBS Group reissued a “neutral” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. The Goldman Sachs Group restated a “buy” rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Citigroup reiterated a “buy” rating and issued a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a research report on Thursday, December 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, January 21st. Finally, Wells Fargo & Company raised their price target on Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $96.14.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.